Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Alibaba Re-Starts $1.4 Billion Bid to Acquire iKang Healthcare

publication date: Mar 13, 2018

Alibaba's investment arm and Yunfeng Capital offered $1.4 billion to acquire iKang Healthcare, a chain of private China healthcare clinics. Yunfeng is a venture capital firm co-founded by Jack Ma, the founder and CEO of Alibaba. Most likely, if the deal succeeds, Alibaba will incorporate iKang's 110 clinics into its own network of online/offline healthcare offerings. Nearly two years ago, Yunfeng made a similar offer, bidding up to $1.6 billion for iKang, an offer that topped one from a rival chain, Meinian Onehealth. However, Yunfeng never closed the deal. More details....

Stock Symbols: (NYSE: BABA) (NSDQ: KANG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020